Alnylam Pharmaceuticals, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -0.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $1.44 | $1.21 | -16.0% | Miss | Q2 FY26 call |
| Q1 FY26 | $0.91 | $1.51 | +65.9% | Beat | |
| Q3 FY25 | not reported | $1.84 | not reported | not reported | |
| Q2 FY25 | $-0.58 | $-0.52 | +10.3% | Beat | Q2 FY25 call |
| Q1 FY25 | not reported | $-0.44 | not reported | not reported | |
| Q4 FY24 | $-0.68 | $-0.65 | +4.4% | Beat | |
| Q3 FY24 | $-1.02 | $-0.87 | +14.7% | Beat | |
| Q2 FY24 | not reported | $-0.13 | not reported | not reported | |
| Q1 FY24 | $-1.26 | $-0.52 | +58.7% | Beat | |
| Q4 FY23 | $-1.20 | $-1.10 | +8.3% | Beat | |
| Q3 FY23 | not reported | $1.15 | not reported | not reported | |
| Q2 FY23 | $-1.72 | $-2.21 | -28.5% | Miss |
Back to ALNY overview · ALNY holders · ALNY KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.